Scripps lured to Sunshine State

Article Abstract:

Scripps Research Institute, La Jolla, CA is opening a research institute in Florida, USA due to the persuasion of Florida, with the aim of boosting the local economy. However, Industrial observers feel that the bloom of Florida is doubtful due to the lack of additional facilities in the state for a biotech venture.

Facilities & equipment, Research & Development, Scientific Research and Development Services, Parent-to-subsidiary activities, Subsidiary-to-parent activities, Research & Development NEC, Research institutes, Buildings and facilities, Scripps Clinic and Research Foundation, Subsidiaries, divisions and units

---

Companies jostle for access to public markets

Article Abstract:

US biotech industry completes its first spate of initial public offerings (IPO) which gave an investment opportunity to company executives. The entire sector can be affected if too many companies attempt to access public exchanges that lack investors committed to biotech.

Strategy & planning, Financial management, Drugs, Planning, Biotechnology industry, Biotechnology industries, Finance, Company investment, Investments, Investors, Going public (Securities), Initial public offerings, Company public offering, Company business planning, Company financing

---

Increasing number of companies found ineligible for SBIR funding

Article Abstract:

Small Business Innovation Research (SBIR) program is established in 1982 to increase technological innovation and produce commercially viable products and services. The criteria for the eligibility of companies for SBIR funding are mentioned.

Product standards, safety, & recalls, Administration of General Economic Programs, Small Business Aid Programs, Standards, Research grants, Research funding, Small business assistance

Similar abstracts:

• Abstracts: Boca investerings reversed- no non-tax business purpose for partnership is fatal
• Abstracts: Basis increase denied to shareholder in related party loan restructuring
• Abstracts: Let's be frank. A case for consensus. You pollute, you pay
• Abstracts: India's strategy to bridge the public-private divide. Kiran Mazumdar-Shaw. Indian biogenerics industry emerges
• Abstracts: Uncertainty surrounds cancer vaccine review at FDA. Despite glacial progress, US government signals support for personalized medicine

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.